USFDA approval renewed for Wanbury´s Patalganga Plant

Wanbury Ltd has announced that USFDA has renewed its approval for the Company´s multi product API facility at Patalganga, from where the Company will manufacture three new products namely Tramadol, Amytriptyline and Paroxetine. The Patalganga Plant had received the USFDA approval earlier in 2002.

The Patalganga Plant will continue to manufacture existing products like Metformin and Salsalate.

Source : Equity Bulls

Keywords